![Christopher Chai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Chai
Director/Board Member at
SURROZEN, INC.
Net worth: 51 994 $ as of 30/07/2026
Profile
Christopher Y.
Chai is currently an Independent Director at Surrozen, Inc. since 2021, a Director at Surrozen Operating, Inc. since 2021, a Venture Partner at GSK Equity Investments Ltd. since 2021, and a Venture Partner at SR One Capital Management LP since 2021.
Former roles include Director at Transcriptx, Inc. from 2016 to 2020, Chief Financial & Accounting Officer at Principia Biopharma, Inc. from 2013 to 2020, Treasurer, VP & Head-Investor Relations at CV Therapeutics, Inc. in 2006, CFO, Senior VP & Investor Relations Contact at MAP Pharmaceuticals LLC from 2011 to 2013, and Principal at JPMorgan Chase & Co. Education includes undergraduate studies at Cornell University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SURROZEN INC 0.02% | 12/05/2026 | 2,341 ( 0.02% ) | 51 994 $ | 30/07/2026 |
Christopher Chai active positions
| Companies | Position | Start |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 31/03/2021 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 10/02/2021 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Director/Board Member | 05/05/2021 |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 31/12/2020 |
Former positions of Christopher Chai
| Companies | Position | End |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Director of Finance/CFO | 27/09/2020 |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Director/Board Member | 31/12/2019 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Director of Finance/CFO | 31/12/2012 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Public Communications Contact | 31/12/2005 |
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | - |
Training of Christopher Chai
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
73
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Health Technology |
JPMorgan Chase & Co.
 JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a R&D driven and AI-powered biopharma company | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Surrozen, Inc.
 Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
- Stock Market
- Insiders
- Christopher Chai
